Financial Survey: Oncology Institute (NASDAQ:TOI) vs. BG Medicine (OTCMKTS:BGMD)

Oncology Institute (NASDAQ:TOI – Get Free Report) and BG Medicine (OTCMKTS:BGMD – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

36.9% of Oncology Institute shares are held by institutional investors. 8.5% of Oncology Institute shares are held by insiders. Comparatively, 6.5% of BG Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Oncology Institute and BG Medicine’s net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Oncology Institute and BG Medicine”s gross revenue, earnings per share (EPS) and valuation.

BG Medicine has lower revenue, but higher earnings than Oncology Institute.

Analyst Ratings

This is a summary of current ratings and target prices for Oncology Institute and BG Medicine, as provided by MarketBeat.

Oncology Institute currently has a consensus price target of $7.00, suggesting a potential upside of 75.00%. Given Oncology Institute’s stronger consensus rating and higher probable upside, equities analysts plainly believe Oncology Institute is more favorable than BG Medicine.

Volatility & Risk

Oncology Institute has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, BG Medicine has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Summary

Oncology Institute beats BG Medicine on 6 of the 9 factors compared between the two stocks.

About Oncology Institute

(Get Free Report)

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About BG Medicine

(Get Free Report)

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.